Author Archives for Adeline Chauvigné

Valneva provides further update on its COVID-19 activities

Valneva, a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities. The company had previously communicated... View Article

Rédigé par Adeline Chauvigné, le 2022-09-26

Valneva provides further update on its COVID-19 activities

Valneva, a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities. The company had previously communicated... View Article

Pherecydes Pharma successfully completes €3.1 million capital increase

Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the... View Article

Rédigé par Adeline Chauvigné, le 2022-09-22

Pherecydes Pharma successfully completes €3.1 million capital increase

Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the... View Article

Same™ by i-SEP medical device has obtained the CE mark and started marketing

i-SEP announces the CE marking and marketing of its autotransfusion medical device: same™ by i-SEP. For the past several months... View Article

Rédigé par Adeline Chauvigné, le 2022-09-19

Same™ by i-SEP medical device has obtained the CE mark and started marketing

i-SEP announces the CE marking and marketing of its autotransfusion medical device: same™ by i-SEP. For the past several months... View Article

Biofortis is part of the national project Le French Gut, to accelerate the science of the microbiota

READ THE PRESS RELEASE Biofortis as a unique full service CRO providing Nutrition Clinical Trials, Microbiome Investigation and Data Science... View Article

Rédigé par Adeline Chauvigné, le 2022-09-16

Biofortis is part of the national project Le French Gut, to accelerate the science of the microbiota

READ THE PRESS RELEASE Biofortis as a unique full service CRO providing Nutrition Clinical Trials, Microbiome Investigation and Data Science... View Article

Perha Pharmaceuticals is a laureate of the European Innovation Council (EIC) Accelerator Programme and could receive an €8 M in funding for the development of its lead candidate Leucettinib-21

Perha Pharmaceuticals has been selected by the European Commission under the European Innovation Council (EIC) Accelerator Programme for the development... View Article

Rédigé par Adeline Chauvigné, le 2022-09-30

Perha Pharmaceuticals is a laureate of the European Innovation Council (EIC) Accelerator Programme and could receive an €8 M in funding for the development of its lead candidate Leucettinib-21

Perha Pharmaceuticals has been selected by the European Commission under the European Innovation Council (EIC) Accelerator Programme for the development... View Article

Pherecydes Pharma announces a first registration of its phagogram as an in vitro diagnostic test in accordance with EC Directives

Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the registration... View Article

Rédigé par Adeline Chauvigné, le 2022-09-15

Pherecydes Pharma announces a first registration of its phagogram as an in vitro diagnostic test in accordance with EC Directives

Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the registration... View Article

Naobios x GenSensor: a partnership for bioprocess optimization

A partnership between three members of Atlanpole Biotherapies:  Naobios, Clean Biologics and GenSensor. The collaboration aims at bioprocess optimization through joint bioproduction expertise. Two companies providing expert... View Article

Rédigé par Adeline Chauvigné, le 2022-09-15

Naobios x GenSensor: a partnership for bioprocess optimization

A partnership between three members of Atlanpole Biotherapies:  Naobios, Clean Biologics and GenSensor. The collaboration aims at bioprocess optimization through joint bioproduction expertise. Two companies providing expert... View Article

VitaDX signs a strategic partnership with the XPath group for the use of its VisioCyt® software solution

XPath, a group of medical specialists in pathological anatomy and cytology, a player in this medical specialty that has made... View Article

Rédigé par Adeline Chauvigné, le 2022-09-08

VitaDX signs a strategic partnership with the XPath group for the use of its VisioCyt® software solution

XPath, a group of medical specialists in pathological anatomy and cytology, a player in this medical specialty that has made... View Article

AbolerIS Pharma selected for the HealthTech For Care Innovation Award

The HealthTech For Care Innovation Award will be presented for the first time at the HealthTech Innovation Days on October... View Article

Rédigé par Adeline Chauvigné, le 2022-09-28

AbolerIS Pharma selected for the HealthTech For Care Innovation Award

The HealthTech For Care Innovation Award will be presented for the first time at the HealthTech Innovation Days on October... View Article

Valneva reports further positive phase 3 immunogenicity and the first heterologous booster tesults for its inactivated, adjuvanted COVID-19 vaccine VLA2001

Valneva, a specialty vaccine company, reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001. Additional readouts... View Article

Rédigé par Adeline Chauvigné, le 2022-09-06

Valneva reports further positive phase 3 immunogenicity and the first heterologous booster tesults for its inactivated, adjuvanted COVID-19 vaccine VLA2001

Valneva, a specialty vaccine company, reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001. Additional readouts... View Article